glp-1 parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including cardiovascular and neurodegenerative disorders Frontiers | Molecular mechanisms underlying

Patients should report ongoing gastrointestinal symptoms, signs of dehydration, or thirst that seems disproportionate to fluid intake

A: Visible improvement usually starts after 4 weeks of consistent use

It stimulates growth hormone release by acting on the ghrelin/growth hormone secretagogue receptor (GHS-R) without significantly affecting cortisol, prolactin, or ACTH levels

These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease

In the UK, buying and injecting B12 yourself is strongly advised against